femseven conti 50/7 microgram/day transdermal patch
merck serono limited - estradiol hemihydrate levonorgestrel - transdermal patch - 50/7 microgram/day
femseven sequi microgram transdermal patch
merck serono limited - estradiol hemihydrate levonorgestrel - transdermal patch - microgram
feminova plus 50 µg/24 h - 10 µg/24 h transderm. patch sachet
theramex ireland ltd. - estradiol hemihydrate 1,5 mg (component 1); levonorgestrel 1,5 mg (component 2); estradiol hemihydrate 1,5 mg (component 2) - transdermal patch - 50 µg/24 h - 10 µg/24 h - estradiol hemihydrate 1.5 mg; estradiol hemihydrate 1.5 mg; levonorgestrel 1.5 mg - levonorgestrel and estrogen
estradiol sun 10 micrograms vaginal tablets
sun pharmaceutical industries europe b.v. - estradiol - vaginal tablet - 10 microgram(s) - estradiol
ethinylestradiol/drospirenone leon farma & placebo 0.03 mg/3 mg film-coated tablets
laboratorios leon farma, s.a. - ethinylestradiol; drospirenone - film-coated tablet - 0.03/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol
estradiol tablet
pharmascience inc - estradiol - tablet - 0.5mg - estradiol 0.5mg - estrogens
estradiol tablet
pharmascience inc - estradiol - tablet - 1mg - estradiol 1mg - estrogens
estradiol tablet
pharmascience inc - estradiol - tablet - 2mg - estradiol 2mg - estrogens
depo-estradiol- estradiol cypionate injection
pharmacia & upjohn company llc - estradiol cypionate (unii: 7e1dv054lo) (estradiol - unii:4ti98z838e) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: estrogens should not be used in individuals with any of the following conditions: there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobutanol anhydrous (chloral derivative) added as a preservative may be habit forming.
depo-estradiol- estradiol cypionate injection
physicians total care, inc. - estradiol cypionate (unii: 7e1dv054lo) (estradiol cypionate - unii:7e1dv054lo) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: - moderate to severe vasomotor symptoms associated with the menopause. - hypoestrogenism due to hypogonadism. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - depo-estradiol should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for depo-estradiol in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobu